BETA


2014/2133(DEC) 2013 discharge: IMI Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead CONT CZARNECKI Ryszard (icon: ECR ECR) MARINESCU Marian-Jean (icon: PPE PPE), BALČYTIS Zigmantas (icon: S&D S&D), DLABAJOVÁ Martina (icon: ALDE ALDE), ŠOLTES Igor (icon: Verts/ALE Verts/ALE), VALLI Marco (icon: EFDD EFDD)
Committee Opinion ENVI
Committee Opinion ITRE
Lead committee dossier:

Events

2015/09/30
   Final act published in Official Journal
Details

PURPOSE: to grant discharge to the IMI Joint Undertaking for the financial year 2013.

NON LEGISLATIVE ACT: Decision (EU) 2015/1699 of the European Parliament on discharge in respect of the implementation of the budget of the Joint Technology Initiative on Innovative Medicines for the financial year 2013.

CONTENT: with the present decision, the European Parliament grants discharge to the Executive Director of the Innovative Medicines Initiative 2 Joint Undertaking for the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013.

This decision is in line with the European Parliament's resolution adopted on 29 April 2015 and comprises a series of observations that form an integral part of the discharge decision (please refer to the summary of the opinion of 29 April 2015).

Amongst Parliament’s main observations, the latter noted an IT risk for the Joint Undertaking's specific IT systems as well as the common infrastructure it shares with the FCH, Clean Sky, ENIAC and Artemis Joint Undertakings. It asked the Joint Undertaking to change control processes in the infrastructure.

2015/04/29
   EP - Results of vote in Parliament
2015/04/29
   EP - Decision by Parliament, 1st reading/single reading
Details

The European Parliament decided by 286 votes to 402, with 7 abstentions, to defer the decision to postpone granting discharge to Executive Director of the Innovative Medicines Initiative 2 (IMI) Joint Undertaking discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013. With the rejection of the decision to postpone, discharge shall be granted and the accounts shall be deemed closed (see Annex V, Article 5(1) of the Rules of Procedure).

Parliament also adopted by 633 votes to 42, with 17 abstentions, a resolution containing a number of recommendations that form an integral part of the discharge decision and as well as the general recommendations that appear in the resolution on performance, financial management and control of EU agencies :

Budgetary and financial management : Parliament noted that the error rate resulting from audits was at 5.82%, which meant that a qualified opinion was issued on the legality and the regularity of the transactions underlying the accounts of the Joint Undertaking, in view of the fact that the rate was above the materiality threshold of 2%. Whilst acknowledging that follow-up actions related to audited beneficiaries with detected errors were launched, Parliament asked for an action plan with clear objectives aimed at fixing the deficiencies and errors identified by the Court to be submitted to the discharge authority in a timely manner. It also asked IMI 2 to provide the discharge authority with detailed information on the in-kind contributions of EFPIA companies especially on the type of the in-kind contributions and their respective value. Members called on the Joint Undertaking to submit a report to the discharge authority concerning the contributions of all members other than the Commission including the application of the methodology for evaluating in-kind contributions, together with an assessment by the Commission.

Internal control : Parliament observed that the Commission's Internal Audit Service (IAS) performed an assurance engagement of project management and reporting on operational performance, and included recommendations regarding improvements particularly regarding risk assessment of the Joint Undertaking's specific IT systems as well as the common infrastructure it shares with the FCH, Clean Sky, ENIAC and ARTEMIS Joint Undertakings.

Parliament went on to make a series of observation on conflicts of interests at the Joint Undertaking as well as on the management of calls for proposals and the legal framework of IMI 2.

Regarding the conflict of interests : Parliament took note that in order to prevent conflicts of interest in respect to its Governing Board members, experts and employees, the Joint Undertaking has put in place specific measures which are included in the rules of procedure of both the Governing Board and the Scientific Committee, as well as in the documentation on the code of conduct and conflicts of interest in the case of independent experts during evaluation. The Joint Undertaking has also adopted an updated and comprehensive policy on conflicts of interest for both management and staff members.

Other observations : lastly, Parliament called on IMI 2 to submit a report to the discharge authority on the social-economic benefits of the already completed projects and for that report to be submitted to the discharge authority together with an assessment by the Commission. It recalled that the discharge authority had previously requested the Court to draw up a special report on the capacity of the joint undertakings, together with their private partners, to ensure added value and efficient execution of Union research, technological development and demonstration programmes.

Documents
2015/04/29
   EP - End of procedure in Parliament
2015/04/28
   EP - Debate in Parliament
2015/03/31
   EP - Committee report tabled for plenary, single reading
Details

The Committee on Budgetary Control adopted the report by Ryszard CZARNECKI (ECR, PL) on discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines (IMI) for the financial year 2013.

It called on the European Parliament to postpone its decision on granting the Executive Director of IMI 2 discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the IMI for the financial year 2013.

Members postponed the closure of the accounts of the Joint Undertaking for the financial year 2013. At the same time, they made a number of recommendations that needed to be taken into account when the discharge is granted, in addition to the general recommendations that appear in the draft resolution on performance, financial management and control of EU agencies .

Budgetary and financial management: Members noted that the error rate resulting from audits was at 5.82%, which meant that a qualified opinion was issued on the legality and the regularity of the transactions underlying the accounts of the Joint Undertaking, in view of the fact that the rate was above the materiality threshold of 2%. Whilst acknowledging that follow-up actions related to audited beneficiaries with detected errors were launched, Members asked for an action plan with clear objectives aimed at fixing the deficiencies and errors identified by the Court to be submitted to the discharge authority in a timely manner. Members also asked IMI 2 to provide the discharge authority with detailed information on the in-kind contributions of EFPIA companies especially on the type of the in-kind contributions and their respective value. They also called on the Joint Undertaking to submit a report to the discharge authority concerning the contributions of all members other than the Commission including the application of the methodology for evaluating in-kind contributions, together with an assessment by the Commission. Internal control: the committee observed that the Commission's Internal Audit Service (IAS) performed an assurance engagement of project management and reporting on operational performance, and included recommendations regarding improvements particularly regarding risk assessment of the Joint Undertaking's specific IT systems as well as the common infrastructure it shares with the FCH, Clean Sky, ENIAC and ARTEMIS Joint Undertakings.

Members went on to make a series of observation on conflicts of interests at the Joint Undertaking as well as on the management of calls for proposals and the legal framework of IMI 2.

Other observations: lastly, the committee called on IMI 2 to submit a report to the discharge authority on the social-economic benefits of the already completed projects and for that report to be submitted to the discharge authority together with an assessment by the Commission. It recalled that the discharge authority had previously requested the Court to draw up a special report on the capacity of the joint undertakings, together with their private partners, to ensure added value and efficient execution of Union research, technological development and demonstration programmes.

Documents
2015/03/23
   EP - Vote in committee, 1st reading/single reading
2015/03/05
   EP - Amendments tabled in committee
Documents
2015/01/30
   CSL - Document attached to the procedure
Details

Having examined the revenue and expenditure accounts for the financial year 2013 and the balance sheet at 31 December 2013 of the Innovative Medicines Initiative Joint Undertaking (IMI), and the report by the Court of Auditors on the annual accounts of the Joint Undertaking for the financial year 2013,accompanied by the Joint Undertaking's replies to the Court's observations, the Council recommended that the European Parliament give a discharge to the Executive Director of the successor Joint Undertaking in respect of the implementation of the budget of the Joint Undertaking for the financial year 2013.

The Council recalled that the Innovative Medicines Initiative 2 Joint Undertaking (IMI 2) has replaced and succeeded the Innovative Medicines Initiative Joint Undertaking and discharge should therefore be given to the Executive Director of IMI 2.

The Council welcomed the Court's opinion that, in all material respects, the Joint Undertaking's annual accounts present fairly its financial position as at 31 December 2013 and the results of its operations and its cash flows for the year then ended, in accordance with the provisions of the Joint Undertaking's Financial Regulation and the accounting rules adopted by the Commission's accounting officer

However, the Council regretted the Court's qualified opinion on the legality and regularity of the transactions underlying the accounts , due to the error rate above the materiality threshold detected during its ex-post audits.

While recognising the improvements compared to 2012, the Council urged IMI 2 to take the necessary corrective actions to recover the ineligible expenditure and to decrease the rate of error in order to achieve an unqualified opinion of the Court. In addition, the following observations are made:

carryovers: in order to avoid excessive carry-overs, the Council called on IMI 2 to pay due attention to the proper implementation of commitment and payment appropriations in the course of the budgetary year and to decommit unused appropriations if necessary; internal controls: the Council welcomed the developments achieved so far in establishing effective and reliable internal control systems and invites IMI 2 to continue the effort in line with the Court's recommendations; results of research : the Council also invited the successor Joint Undertaking to improve the monitoring of research results.

Documents
2015/01/28
   EP - Committee draft report
Documents
2014/10/21
   CofA - Court of Auditors: opinion, report
Details

PURPOSE: presentation of the EU Court of Auditors’ report on the annual accounts of the Innovative Medicines Initiative Joint Undertaking for the financial year 2013, together with the Joint Undertaking’s replies.

CONTENT: in accordance with the tasks conferred on the Court of Auditors by the Treaty on the Functioning of the European Union, the Court presents to the European Parliament and to the Council, in the context of the discharge procedure, a Statement of Assurance as to the reliability of the annual accounts of each institution, body or agency of the EU, and the legality and regularity of the transactions underlying them, on the basis of an independent external audit.

This audit concerned, amongst others, the annual accounts of the Innovative Medicines Initiative (IMI) Joint Undertaking.

Statement of assurance : pursuant to the provisions of Article 287 of the Treaty on the Functioning of the European Union (TFEU), the Court has audited:

the annual accounts of the IMI Joint Undertaking, which comprise the financial statements and the reports on the implementation of the budget for the financial year ended 31 December 2013; the legality and regularity of the transactions underlying those accounts.

Opinion on the reliability of the accounts : in the Court’s opinion, the Joint Undertaking’s annual accounts present fairly, in all material respects, its financial position as at 31 December 2013 and the results of its operations and its cash flows for the year then ended, in accordance with the provisions of its financial rules and the accounting rules adopted by the Commission’s accounting officer.

Basis for a qualified opinion on the legality and regularity of the transactions underlying the accounts : in the Court’s opinion, except for the effects of the matter described below, the transactions underlying the annual accounts of the Joint Undertaking for the year ended 31 December 2013 are, in all material respects, legal and regular. However, the Court noted that under the Joint Undertaking’s ex post audit Strategy, as of June 2014, 14 out of 40 ex post audits of the second representative sample had been finalised. The detected error rate resulting from these audits is 2.3%. The Court considered that a qualified opinion was issued for the IMI since there was insufficient appropriate audit evidence on which to base the opinion and the possible effects are considered material but not pervasive.

The audit approach taken by the Court comprises analytical audit procedures, testing of transactions at the level of the Joint Undertaking and an assessment of key controls of the supervisory and control systems. This is supplemented by evidence provided by the work of other auditors and an analysis of management representations and of annual activity reports.

The 2013 audit placed special emphasis on ex post audits.

At the end of this audit, the Court concluded the following :

conflicts of interest : the IMI Joint Undertaking has put in place specific measures to prevent conflicts of interest in respect to its Governing Board members, experts and employees. Furthermore, in April 2013 the Joint Undertaking adopted an updated and comprehensive policy on conflicts of interest for both management and staff.

Cross-cutting remarks for all the Joint undertakings : the prevention of conflicts of interest is addressed by most Joint Undertakings by the adoption of specific rules and by the development of tools to document all related information. An Interim Evaluation was performed over 2013 assessing all Joint Undertakings in terms of relevance, efficiency, effectiveness and research quality. The reports, while positive, also highlighted areas for further improvement. In general, all Joint Undertakings have produced reliable accounts but there is room for improvement.

Joint Undertaking’s replies : the Joint Undertaking replied point by point to all of the technical elements highlighted by the Court of Auditors. It noted that all errors detected by IMI from these audits have since been communicated to the audited beneficiaries and the required follow-up actions have been launched. In parallel, IMI has continued to take concrete preventive measures to mitigate the risk of future errors in beneficiaries’ cost claims. These have included the organisation of frequent financial workshops for participants that focus on recurrent causes of errors and prevention, as well as the regular updating of IMI’s Financial Guidelines for participants explaining in detail the provisions of the IMI model grant agreement. Furthermore, IMI has carried on implementing an intensive annual programme of ex post audits.

IMI will carry on monitoring closely the evolution of the error rate and the impact of its actions, updating accordingly its ex post audit strategy to reflect latest indications and any new emerging risks.

As regards the activities of the Joint Undertaking in 2013 , the report refers to the Annual Activity Report 2013 which can be found at www.imi.europa.eu .

It should be noted that the budget for the Joint Undertaking for 2013 amount to EUR 255 715 919 in commitment appropriations and EUR 130 558 622 in payment appropriations.

2014/10/20
   EP - Committee referral announced in Parliament, 1st reading/single reading
2014/09/26
   EP - CZARNECKI Ryszard (ECR) appointed as rapporteur in CONT
2014/07/30
   EC - Non-legislative basic document published
Details

PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2013, as part of the 2013 discharge procedure.

Analysis of the accounts of the Joint Technology Initiative on Innovative Medicines (IMI) .

CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2013 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the IMI Joint Undertaking.

The document contains the figures on which the discharge procedure is based.

Discharge procedure of the EU Joint Undertakings : the EU Budget finances a wide range of policies and programmes throughout the EU. In accordance with the priorities set by the European Parliament and the Council in the multi-annual financial framework (MFF), the European Commission carries out specific programmes, activities and projects in the field with the technical support of some specialised agencies.

The consolidated annual accounts of the EU provide information on the activities of the institutions, agencies and other bodies of the EU from a budgetary and accrual accounting perspective.

The consolidated reports on the implementation of the general budget of the EU include the budget implementation of all Institutions. Agencies and Joint Undertakings (JUs) do not have a separate budget inside the EU budget ; and they are partially financed by a Commission budget subsidy.

Each JU is subject to its own discharge procedure.

IMI : in 2013, the tasks and budget of the Joint Undertaking were as follows:

description of the tasks of the Joint Undertaking : the IMI Joint undertaking, which is located in Brussels, was set up in 2007 by Council Regulation (EC) No 73/2008 for a period of 10 years. The IMI Joint Undertaking supports pre-competitive pharmaceutical research and development in the Member States and associated countries, aiming at increasing the research investment in the biopharmaceutical sector and promotes the involvement of small and medium-sized enterprises (SME) in its activities; accounts of the JU : the maximum indicative contribution of the Commission to cover running costs and research activities is EUR 1 billion up to 31.12.2017. The cumulative unrecognised share of losses is EUR 16 million.

Please also consult the final accounts of IMI Joint Undertaking .

Documents

Activities

Votes

A8-0106/2015 - Ryszard Czarnecki - Décision (ensemble du texte)

2015/04/29 Outcome: -: 402, +: 286, 0: 7
DE FI PL CY DK LT NL EL IE LU SK SE LV GB SI MT EE PT BE HR CZ FR AT BG HU ES IT RO
Total
90
12
47
6
11
9
26
20
10
6
13
17
7
54
8
6
6
20
19
11
21
70
18
14
19
52
70
32
icon: ECR ECR
63

Finland ECR

For (1)

1

Netherlands ECR

2

Greece ECR

For (1)

1

Croatia ECR

For (1)

1

Czechia ECR

2

Bulgaria ECR

1
icon: GUE/NGL GUE/NGL
51

Finland GUE/NGL

For (1)

1

Cyprus GUE/NGL

2

Denmark GUE/NGL

For (1)

1

Netherlands GUE/NGL

3

Sweden GUE/NGL

For (1)

1

United Kingdom GUE/NGL

1

Portugal GUE/NGL

Abstain (1)

4
icon: Verts/ALE Verts/ALE
48

Finland Verts/ALE

For (1)

1

Denmark Verts/ALE

For (1)

1

Lithuania Verts/ALE

For (1)

1

Netherlands Verts/ALE

2

Luxembourg Verts/ALE

For (1)

1

Latvia Verts/ALE

1

United Kingdom Verts/ALE

5

Slovenia Verts/ALE

For (1)

1

Estonia Verts/ALE

For (1)

1

Belgium Verts/ALE

2

Croatia Verts/ALE

For (1)

1

Austria Verts/ALE

3

Hungary Verts/ALE

2
icon: NI NI
46

Germany NI

For (1)

1

Hungary NI

2

Spain NI

1
icon: EFDD EFDD
31

Poland EFDD

1

Lithuania EFDD

2

Sweden EFDD

2

Czechia EFDD

Against (1)

1

France EFDD

Against (1)

1
icon: ALDE ALDE
64

Denmark ALDE

3

Lithuania ALDE

2

Ireland ALDE

Against (1)

1

Luxembourg ALDE

Against (1)

1

Latvia ALDE

1

United Kingdom ALDE

Against (1)

1

Slovenia ALDE

Against (1)

1

Estonia ALDE

3

Portugal ALDE

2

Croatia ALDE

2

Austria ALDE

Against (1)

1

Romania ALDE

3
icon: PPE PPE
207

Cyprus PPE

Against (1)

2

Lithuania PPE

Against (1)

2

Luxembourg PPE

For (1)

3
5

Malta PPE

For (1)

3

Estonia PPE

Against (1)

1

Belgium PPE

For (1)

4
icon: S&D S&D
184

Finland S&D

2

Cyprus S&D

2
3

Lithuania S&D

2

Netherlands S&D

3

Ireland S&D

Against (1)

1

Luxembourg S&D

Against (1)

1

Latvia S&D

Against (1)

1

Slovenia S&D

Against (1)

1

Malta S&D

3

Estonia S&D

Against (1)

1

Croatia S&D

For (1)

Against (1)

2

Czechia S&D

For (1)

4

Bulgaria S&D

3

A8-0106/2015 - Ryszard Czarnecki - Résolution

2015/04/29 Outcome: +: 633, -: 42, 0: 17
DE IT ES PL GB RO FR CZ PT BE HU NL BG AT SE FI EL SK DK IE LT HR SI LV LU EE CY MT
Total
89
69
50
48
54
32
70
21
20
19
19
26
14
18
17
12
20
13
11
10
9
11
8
7
6
6
6
6
icon: PPE PPE
208
2

Luxembourg PPE

3

Estonia PPE

For (1)

1
icon: S&D S&D
183

Netherlands S&D

3
3

Ireland S&D

For (1)

1

Croatia S&D

2

Slovenia S&D

For (1)

1

Latvia S&D

1

Luxembourg S&D

For (1)

1

Estonia S&D

For (1)

1

Cyprus S&D

2

Malta S&D

3
icon: ALDE ALDE
64

United Kingdom ALDE

Against (1)

1

Romania ALDE

3

Austria ALDE

For (1)

1

Denmark ALDE

3

Ireland ALDE

For (1)

1

Lithuania ALDE

2

Croatia ALDE

For (1)

Against (1)

2

Slovenia ALDE

For (1)

1

Latvia ALDE

1

Luxembourg ALDE

For (1)

1

Estonia ALDE

3
icon: ECR ECR
63

Czechia ECR

2

Netherlands ECR

2

Bulgaria ECR

1

Finland ECR

For (1)

1

Greece ECR

For (1)

1

Slovakia ECR

Abstain (1)

3

Croatia ECR

For (1)

1
icon: Verts/ALE Verts/ALE
48

United Kingdom Verts/ALE

5

Belgium Verts/ALE

2

Hungary Verts/ALE

2

Netherlands Verts/ALE

2

Austria Verts/ALE

3

Finland Verts/ALE

For (1)

1

Denmark Verts/ALE

For (1)

1

Lithuania Verts/ALE

For (1)

1

Croatia Verts/ALE

For (1)

1

Slovenia Verts/ALE

For (1)

1

Latvia Verts/ALE

1

Luxembourg Verts/ALE

For (1)

1

Estonia Verts/ALE

For (1)

1
icon: GUE/NGL GUE/NGL
48

United Kingdom GUE/NGL

1

Netherlands GUE/NGL

3

Sweden GUE/NGL

For (1)

1

Finland GUE/NGL

For (1)

1

Denmark GUE/NGL

For (1)

1

Cyprus GUE/NGL

2
icon: EFDD EFDD
31

Poland EFDD

1

France EFDD

1

Czechia EFDD

Abstain (1)

1

Sweden EFDD

2

Lithuania EFDD

2
icon: NI NI
46

Germany NI

For (1)

1

Spain NI

1

Poland NI

2

Hungary NI

2

Netherlands NI

4
AmendmentsDossier
13 2014/2133(DEC)
2015/03/05 CONT 13 amendments...
source: 549.353

History

(these mark the time of scraping, not the official date of the change)

committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Budgetary Control
committee
CONT
rapporteur
name: CZARNECKI Ryszard date: 2014-09-26T00:00:00 group: European Conservatives and Reformists abbr: ECR
shadows
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Budgetary Control
committee
CONT
date
2014-09-26T00:00:00
rapporteur
name: CZARNECKI Ryszard group: European Conservatives and Reformists abbr: ECR
shadows
events/0
date
2014-07-30T00:00:00
type
Non-legislative basic document published
body
EC
docs
summary
events/0
date
2014-07-30T00:00:00
type
Non-legislative basic document published
body
EC
docs
summary
events/3/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2015-0106&language=EN
New
http://www.europarl.europa.eu/doceo/document/A-8-2015-0106_EN.html
events/6/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2015-0167
New
http://www.europarl.europa.eu/doceo/document/TA-8-2015-0167_EN.html
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Budgetary Control
committee
CONT
date
2014-09-26T00:00:00
rapporteur
name: CZARNECKI Ryszard group: European Conservatives and Reformists abbr: ECR
shadows
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Budgetary Control
committee
CONT
date
2014-09-26T00:00:00
rapporteur
name: CZARNECKI Ryszard group: European Conservatives and Reformists abbr: ECR
shadows
events/0
date
2014-07-30T00:00:00
type
Non-legislative basic document published
body
EC
docs
summary
events/0
date
2014-07-30T00:00:00
type
Non-legislative basic document published
body
EC
docs
summary
activities
  • date: 2014-07-30T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2014/0510/COM_COM(2014)0510_FR.pdf title: COM(2014)0510 type: Non-legislative basic document published celexid: CELEX:52014DC0510:EN body: EC commission: DG: url: http://ec.europa.eu/dgs/budget/ title: Budget Commissioner: GEORGIEVA Kristalina type: Non-legislative basic document published
  • date: 2014-10-20T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP shadows: group: EPP name: MARINESCU Marian-Jean group: S&D name: BALČYTIS Zigmantas group: ALDE name: DLABAJOVÁ Martina group: Verts/ALE name: ŠOLTES Igor group: EFD name: VALLI Marco responsible: True committee: CONT date: 2014-09-26T00:00:00 committee_full: Budgetary Control rapporteur: group: ECR name: CZARNECKI Ryszard body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
  • date: 2015-03-23T00:00:00 body: EP type: Vote in committee, 1st reading/single reading committees: body: EP shadows: group: EPP name: MARINESCU Marian-Jean group: S&D name: BALČYTIS Zigmantas group: ALDE name: DLABAJOVÁ Martina group: Verts/ALE name: ŠOLTES Igor group: EFD name: VALLI Marco responsible: True committee: CONT date: 2014-09-26T00:00:00 committee_full: Budgetary Control rapporteur: group: ECR name: CZARNECKI Ryszard body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
  • date: 2015-03-31T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2015-0106&language=EN type: Committee report tabled for plenary, single reading title: A8-0106/2015 body: EP type: Committee report tabled for plenary, single reading
  • date: 2015-04-28T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20150428&type=CRE type: Debate in Parliament title: Debate in Parliament body: EP type: Debate in Parliament
  • date: 2015-04-29T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=25542&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2015-0167 type: Decision by Parliament, 1st reading/single reading title: T8-0167/2015 body: EP type: Results of vote in Parliament
  • date: 2015-09-30T00:00:00 type: Final act published in Official Journal
commission
  • body: EC dg: Budget commissioner: GEORGIEVA Kristalina
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Budgetary Control
committee
CONT
date
2014-09-26T00:00:00
rapporteur
name: CZARNECKI Ryszard group: European Conservatives and Reformists abbr: ECR
shadows
committees/0
body
EP
shadows
responsible
True
committee
CONT
date
2014-09-26T00:00:00
committee_full
Budgetary Control
rapporteur
group: ECR name: CZARNECKI Ryszard
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
opinion
False
committees/1
body
EP
responsible
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
committees/2
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
opinion
False
committees/2
body
EP
responsible
False
committee_full
Industry, Research and Energy
committee
ITRE
docs
  • date: 2014-10-21T00:00:00 docs: url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:2014:452:TOC title: OJ C 452 16.12.2014, p. 0035 title: N8-0005/2015 summary: PURPOSE: presentation of the EU Court of Auditors’ report on the annual accounts of the Innovative Medicines Initiative Joint Undertaking for the financial year 2013, together with the Joint Undertaking’s replies. CONTENT: in accordance with the tasks conferred on the Court of Auditors by the Treaty on the Functioning of the European Union, the Court presents to the European Parliament and to the Council, in the context of the discharge procedure, a Statement of Assurance as to the reliability of the annual accounts of each institution, body or agency of the EU, and the legality and regularity of the transactions underlying them, on the basis of an independent external audit. This audit concerned, amongst others, the annual accounts of the Innovative Medicines Initiative (IMI) Joint Undertaking. Statement of assurance : pursuant to the provisions of Article 287 of the Treaty on the Functioning of the European Union (TFEU), the Court has audited: the annual accounts of the IMI Joint Undertaking, which comprise the financial statements and the reports on the implementation of the budget for the financial year ended 31 December 2013; the legality and regularity of the transactions underlying those accounts. Opinion on the reliability of the accounts : in the Court’s opinion, the Joint Undertaking’s annual accounts present fairly, in all material respects, its financial position as at 31 December 2013 and the results of its operations and its cash flows for the year then ended, in accordance with the provisions of its financial rules and the accounting rules adopted by the Commission’s accounting officer. Basis for a qualified opinion on the legality and regularity of the transactions underlying the accounts : in the Court’s opinion, except for the effects of the matter described below, the transactions underlying the annual accounts of the Joint Undertaking for the year ended 31 December 2013 are, in all material respects, legal and regular. However, the Court noted that under the Joint Undertaking’s ex post audit Strategy, as of June 2014, 14 out of 40 ex post audits of the second representative sample had been finalised. The detected error rate resulting from these audits is 2.3%. The Court considered that a qualified opinion was issued for the IMI since there was insufficient appropriate audit evidence on which to base the opinion and the possible effects are considered material but not pervasive. The audit approach taken by the Court comprises analytical audit procedures, testing of transactions at the level of the Joint Undertaking and an assessment of key controls of the supervisory and control systems. This is supplemented by evidence provided by the work of other auditors and an analysis of management representations and of annual activity reports. The 2013 audit placed special emphasis on ex post audits. At the end of this audit, the Court concluded the following : conflicts of interest : the IMI Joint Undertaking has put in place specific measures to prevent conflicts of interest in respect to its Governing Board members, experts and employees. Furthermore, in April 2013 the Joint Undertaking adopted an updated and comprehensive policy on conflicts of interest for both management and staff. Cross-cutting remarks for all the Joint undertakings : the prevention of conflicts of interest is addressed by most Joint Undertakings by the adoption of specific rules and by the development of tools to document all related information. An Interim Evaluation was performed over 2013 assessing all Joint Undertakings in terms of relevance, efficiency, effectiveness and research quality. The reports, while positive, also highlighted areas for further improvement. In general, all Joint Undertakings have produced reliable accounts but there is room for improvement. Joint Undertaking’s replies : the Joint Undertaking replied point by point to all of the technical elements highlighted by the Court of Auditors. It noted that all errors detected by IMI from these audits have since been communicated to the audited beneficiaries and the required follow-up actions have been launched. In parallel, IMI has continued to take concrete preventive measures to mitigate the risk of future errors in beneficiaries’ cost claims. These have included the organisation of frequent financial workshops for participants that focus on recurrent causes of errors and prevention, as well as the regular updating of IMI’s Financial Guidelines for participants explaining in detail the provisions of the IMI model grant agreement. Furthermore, IMI has carried on implementing an intensive annual programme of ex post audits. IMI will carry on monitoring closely the evolution of the error rate and the impact of its actions, updating accordingly its ex post audit strategy to reflect latest indications and any new emerging risks. As regards the activities of the Joint Undertaking in 2013 , the report refers to the Annual Activity Report 2013 which can be found at www.imi.europa.eu . It should be noted that the budget for the Joint Undertaking for 2013 amount to EUR 255 715 919 in commitment appropriations and EUR 130 558 622 in payment appropriations. type: Court of Auditors: opinion, report body: CofA
  • date: 2015-01-28T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE541.305 title: PE541.305 type: Committee draft report body: EP
  • date: 2015-01-30T00:00:00 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=5306%2F15&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 05306/2015 summary: Having examined the revenue and expenditure accounts for the financial year 2013 and the balance sheet at 31 December 2013 of the Innovative Medicines Initiative Joint Undertaking (IMI), and the report by the Court of Auditors on the annual accounts of the Joint Undertaking for the financial year 2013,accompanied by the Joint Undertaking's replies to the Court's observations, the Council recommended that the European Parliament give a discharge to the Executive Director of the successor Joint Undertaking in respect of the implementation of the budget of the Joint Undertaking for the financial year 2013. The Council recalled that the Innovative Medicines Initiative 2 Joint Undertaking (IMI 2) has replaced and succeeded the Innovative Medicines Initiative Joint Undertaking and discharge should therefore be given to the Executive Director of IMI 2. The Council welcomed the Court's opinion that, in all material respects, the Joint Undertaking's annual accounts present fairly its financial position as at 31 December 2013 and the results of its operations and its cash flows for the year then ended, in accordance with the provisions of the Joint Undertaking's Financial Regulation and the accounting rules adopted by the Commission's accounting officer However, the Council regretted the Court's qualified opinion on the legality and regularity of the transactions underlying the accounts , due to the error rate above the materiality threshold detected during its ex-post audits. While recognising the improvements compared to 2012, the Council urged IMI 2 to take the necessary corrective actions to recover the ineligible expenditure and to decrease the rate of error in order to achieve an unqualified opinion of the Court. In addition, the following observations are made: carryovers: in order to avoid excessive carry-overs, the Council called on IMI 2 to pay due attention to the proper implementation of commitment and payment appropriations in the course of the budgetary year and to decommit unused appropriations if necessary; internal controls: the Council welcomed the developments achieved so far in establishing effective and reliable internal control systems and invites IMI 2 to continue the effort in line with the Court's recommendations; results of research : the Council also invited the successor Joint Undertaking to improve the monitoring of research results. type: Document attached to the procedure body: CSL
  • date: 2015-03-05T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE549.353 title: PE549.353 type: Amendments tabled in committee body: EP
events
  • date: 2014-07-30T00:00:00 type: Non-legislative basic document published body: EC docs: url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2014&nu_doc=0510 title: EUR-Lex title: COM(2014)0510 summary: PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2013, as part of the 2013 discharge procedure. Analysis of the accounts of the Joint Technology Initiative on Innovative Medicines (IMI) . CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2013 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the IMI Joint Undertaking. The document contains the figures on which the discharge procedure is based. Discharge procedure of the EU Joint Undertakings : the EU Budget finances a wide range of policies and programmes throughout the EU. In accordance with the priorities set by the European Parliament and the Council in the multi-annual financial framework (MFF), the European Commission carries out specific programmes, activities and projects in the field with the technical support of some specialised agencies. The consolidated annual accounts of the EU provide information on the activities of the institutions, agencies and other bodies of the EU from a budgetary and accrual accounting perspective. The consolidated reports on the implementation of the general budget of the EU include the budget implementation of all Institutions. Agencies and Joint Undertakings (JUs) do not have a separate budget inside the EU budget ; and they are partially financed by a Commission budget subsidy. Each JU is subject to its own discharge procedure. IMI : in 2013, the tasks and budget of the Joint Undertaking were as follows: description of the tasks of the Joint Undertaking : the IMI Joint undertaking, which is located in Brussels, was set up in 2007 by Council Regulation (EC) No 73/2008 for a period of 10 years. The IMI Joint Undertaking supports pre-competitive pharmaceutical research and development in the Member States and associated countries, aiming at increasing the research investment in the biopharmaceutical sector and promotes the involvement of small and medium-sized enterprises (SME) in its activities; accounts of the JU : the maximum indicative contribution of the Commission to cover running costs and research activities is EUR 1 billion up to 31.12.2017. The cumulative unrecognised share of losses is EUR 16 million. Please also consult the final accounts of IMI Joint Undertaking .
  • date: 2014-10-20T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
  • date: 2015-03-23T00:00:00 type: Vote in committee, 1st reading/single reading body: EP
  • date: 2015-03-31T00:00:00 type: Committee report tabled for plenary, single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2015-0106&language=EN title: A8-0106/2015 summary: The Committee on Budgetary Control adopted the report by Ryszard CZARNECKI (ECR, PL) on discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines (IMI) for the financial year 2013. It called on the European Parliament to postpone its decision on granting the Executive Director of IMI 2 discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the IMI for the financial year 2013. Members postponed the closure of the accounts of the Joint Undertaking for the financial year 2013. At the same time, they made a number of recommendations that needed to be taken into account when the discharge is granted, in addition to the general recommendations that appear in the draft resolution on performance, financial management and control of EU agencies . Budgetary and financial management: Members noted that the error rate resulting from audits was at 5.82%, which meant that a qualified opinion was issued on the legality and the regularity of the transactions underlying the accounts of the Joint Undertaking, in view of the fact that the rate was above the materiality threshold of 2%. Whilst acknowledging that follow-up actions related to audited beneficiaries with detected errors were launched, Members asked for an action plan with clear objectives aimed at fixing the deficiencies and errors identified by the Court to be submitted to the discharge authority in a timely manner. Members also asked IMI 2 to provide the discharge authority with detailed information on the in-kind contributions of EFPIA companies especially on the type of the in-kind contributions and their respective value. They also called on the Joint Undertaking to submit a report to the discharge authority concerning the contributions of all members other than the Commission including the application of the methodology for evaluating in-kind contributions, together with an assessment by the Commission. Internal control: the committee observed that the Commission's Internal Audit Service (IAS) performed an assurance engagement of project management and reporting on operational performance, and included recommendations regarding improvements particularly regarding risk assessment of the Joint Undertaking's specific IT systems as well as the common infrastructure it shares with the FCH, Clean Sky, ENIAC and ARTEMIS Joint Undertakings. Members went on to make a series of observation on conflicts of interests at the Joint Undertaking as well as on the management of calls for proposals and the legal framework of IMI 2. Other observations: lastly, the committee called on IMI 2 to submit a report to the discharge authority on the social-economic benefits of the already completed projects and for that report to be submitted to the discharge authority together with an assessment by the Commission. It recalled that the discharge authority had previously requested the Court to draw up a special report on the capacity of the joint undertakings, together with their private partners, to ensure added value and efficient execution of Union research, technological development and demonstration programmes.
  • date: 2015-04-28T00:00:00 type: Debate in Parliament body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20150428&type=CRE title: Debate in Parliament
  • date: 2015-04-29T00:00:00 type: Results of vote in Parliament body: EP docs: url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=25542&l=en title: Results of vote in Parliament
  • date: 2015-04-29T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2015-0167 title: T8-0167/2015 summary: The European Parliament decided by 286 votes to 402, with 7 abstentions, to defer the decision to postpone granting discharge to Executive Director of the Innovative Medicines Initiative 2 (IMI) Joint Undertaking discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013. With the rejection of the decision to postpone, discharge shall be granted and the accounts shall be deemed closed (see Annex V, Article 5(1) of the Rules of Procedure). Parliament also adopted by 633 votes to 42, with 17 abstentions, a resolution containing a number of recommendations that form an integral part of the discharge decision and as well as the general recommendations that appear in the resolution on performance, financial management and control of EU agencies : Budgetary and financial management : Parliament noted that the error rate resulting from audits was at 5.82%, which meant that a qualified opinion was issued on the legality and the regularity of the transactions underlying the accounts of the Joint Undertaking, in view of the fact that the rate was above the materiality threshold of 2%. Whilst acknowledging that follow-up actions related to audited beneficiaries with detected errors were launched, Parliament asked for an action plan with clear objectives aimed at fixing the deficiencies and errors identified by the Court to be submitted to the discharge authority in a timely manner. It also asked IMI 2 to provide the discharge authority with detailed information on the in-kind contributions of EFPIA companies especially on the type of the in-kind contributions and their respective value. Members called on the Joint Undertaking to submit a report to the discharge authority concerning the contributions of all members other than the Commission including the application of the methodology for evaluating in-kind contributions, together with an assessment by the Commission. Internal control : Parliament observed that the Commission's Internal Audit Service (IAS) performed an assurance engagement of project management and reporting on operational performance, and included recommendations regarding improvements particularly regarding risk assessment of the Joint Undertaking's specific IT systems as well as the common infrastructure it shares with the FCH, Clean Sky, ENIAC and ARTEMIS Joint Undertakings. Parliament went on to make a series of observation on conflicts of interests at the Joint Undertaking as well as on the management of calls for proposals and the legal framework of IMI 2. Regarding the conflict of interests : Parliament took note that in order to prevent conflicts of interest in respect to its Governing Board members, experts and employees, the Joint Undertaking has put in place specific measures which are included in the rules of procedure of both the Governing Board and the Scientific Committee, as well as in the documentation on the code of conduct and conflicts of interest in the case of independent experts during evaluation. The Joint Undertaking has also adopted an updated and comprehensive policy on conflicts of interest for both management and staff members. Other observations : lastly, Parliament called on IMI 2 to submit a report to the discharge authority on the social-economic benefits of the already completed projects and for that report to be submitted to the discharge authority together with an assessment by the Commission. It recalled that the discharge authority had previously requested the Court to draw up a special report on the capacity of the joint undertakings, together with their private partners, to ensure added value and efficient execution of Union research, technological development and demonstration programmes.
  • date: 2015-04-29T00:00:00 type: End of procedure in Parliament body: EP
  • date: 2015-09-30T00:00:00 type: Final act published in Official Journal summary: PURPOSE: to grant discharge to the IMI Joint Undertaking for the financial year 2013. NON LEGISLATIVE ACT: Decision (EU) 2015/1699 of the European Parliament on discharge in respect of the implementation of the budget of the Joint Technology Initiative on Innovative Medicines for the financial year 2013. CONTENT: with the present decision, the European Parliament grants discharge to the Executive Director of the Innovative Medicines Initiative 2 Joint Undertaking for the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013. This decision is in line with the European Parliament's resolution adopted on 29 April 2015 and comprises a series of observations that form an integral part of the discharge decision (please refer to the summary of the opinion of 29 April 2015). Amongst Parliament’s main observations, the latter noted an IT risk for the Joint Undertaking's specific IT systems as well as the common infrastructure it shares with the FCH, Clean Sky, ENIAC and Artemis Joint Undertakings. It asked the Joint Undertaking to change control processes in the infrastructure.
links
other
  • body: EC dg: url: http://ec.europa.eu/dgs/budget/ title: Budget commissioner: GEORGIEVA Kristalina
procedure/dossier_of_the_committee
Old
CONT/8/01601
New
  • CONT/8/01601
procedure/final/title
Old
OJ L 255 30.09.2015, p. 0386
New
OJ L 255 30.09.2015, p. 0386
procedure/final/url
Old
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2015:255:TOC
New
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2015:255:TOC
procedure/subject
Old
  • 8.70.03.03 2013 discharge
New
8.70.03.03
2013 discharge
activities/0/docs/0/celexid
CELEX:52014DC0510:EN
activities/0/docs/0/url
Old
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2014&nu_doc=0510
New
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2014/0510/COM_COM(2014)0510_FR.pdf
activities/0/docs/0/url
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2014/0510/COM_COM(2014)0510_FR.pdf
New
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2014&nu_doc=0510
activities/6
date
2015-09-30T00:00:00
type
Final act published in Official Journal
procedure/final
url
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2015:255:TOC
title
OJ L 255 30.09.2015, p. 0386
procedure/stage_reached
Old
Procedure completed, awaiting publication in Official Journal
New
Procedure completed
activities/5/docs/0
url
http://www.europarl.europa.eu/oeil/popups/sda.do?id=25542&l=en
type
Results of vote in Parliament
title
Results of vote in Parliament
activities/5/type
Old
Decision by Parliament, 1st reading/single reading
New
Results of vote in Parliament
activities/0/docs/0/celexid
CELEX:52014DC0510:EN
activities/0/docs/0/celexid
CELEX:52014DC0510:EN
activities/0/docs/0/celexid
CELEX:52014DC0510:EN
activities/5/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2015-0167
activities/5/docs/0/text
  • The European Parliament decided by 286 votes to 402, with 7 abstentions, to defer the decision to postpone granting discharge to Executive Director of the Innovative Medicines Initiative 2 (IMI) Joint Undertaking discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines for the financial year 2013. With the rejection of the decision to postpone, discharge shall be granted and the accounts shall be deemed closed (see Annex V, Article 5(1) of the Rules of Procedure).

    Parliament also adopted by 633 votes to 42, with 17 abstentions, a resolution containing a number of recommendations that form an integral part of the discharge decision and as well as the general recommendations that appear in the resolution on performance, financial management and control of EU agencies:

    Budgetary and financial management: Parliament noted that the error rate resulting from audits was at 5.82%, which meant that a qualified opinion was issued on the legality and the regularity of the transactions underlying the accounts of the Joint Undertaking, in view of the fact that the rate was above the materiality threshold of 2%.  Whilst acknowledging that follow-up actions related to audited beneficiaries with detected errors were launched, Parliament asked for an action plan with clear objectives aimed at fixing the deficiencies and errors identified by the Court to be submitted to the discharge authority in a timely manner. It also asked IMI 2 to provide the discharge authority with detailed information on the in-kind contributions of EFPIA companies especially on the type of the in-kind contributions and their respective value. Members called on the Joint Undertaking to submit a report to the discharge authority concerning the contributions of all members other than the Commission including the application of the methodology for evaluating in-kind contributions, together with an assessment by the Commission.

    Internal control: Parliament observed that the Commission's Internal Audit Service (IAS) performed an assurance engagement of project management and reporting on operational performance, and included recommendations regarding improvements particularly regarding risk assessment of the Joint Undertaking's specific IT systems as well as the common infrastructure it shares with the FCH, Clean Sky, ENIAC and ARTEMIS Joint Undertakings.

    Parliament went on to make a series of observation on conflicts of interests at the Joint Undertaking as well as on the management of calls for proposals and the legal framework of IMI 2.

    Regarding the conflict of interests: Parliament took note that in order to prevent conflicts of interest in respect to its Governing Board members, experts and employees, the Joint Undertaking has put in place specific measures which are included in the rules of procedure of both the Governing Board and the Scientific Committee, as well as in the documentation on the code of conduct and conflicts of interest in the case of independent experts during evaluation. The Joint Undertaking has also adopted an updated and comprehensive policy on conflicts of interest for both management and staff members.

    Other observations: lastly, Parliament called on IMI 2 to submit a report to the discharge authority on the social-economic benefits of the already completed projects and for that report to be submitted to the discharge authority together with an assessment by the Commission. It recalled that the discharge authority had previously requested the Court to draw up a special report on the capacity of the joint undertakings, together with their private partners, to ensure added value and efficient execution of Union research, technological development and demonstration programmes.

activities/4/docs
  • url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20150428&type=CRE type: Debate in Parliament title: Debate in Parliament
activities/4/type
Old
Debate scheduled
New
Debate in Parliament
activities/5/docs
  • type: Decision by Parliament, 1st reading/single reading title: T8-0167/2015
activities/5/type
Old
Vote in plenary scheduled
New
Decision by Parliament, 1st reading/single reading
procedure/stage_reached
Old
Awaiting Parliament 1st reading / single reading / budget 1st stage
New
Procedure completed, awaiting publication in Official Journal
activities/4/type
Old
Debate in plenary scheduled
New
Debate scheduled
activities/1/committees/0/shadows/1/group
Old
NI
New
S&D
activities/1/committees/0/shadows/1/mepref
Old
53b2d70eb819f205b0000008
New
4f1ac627b819f25efd000021
activities/1/committees/0/shadows/1/name
Old
ALIOT Louis
New
BALČYTIS Zigmantas
activities/1/committees/0/shadows/2
group
ALDE
name
DLABAJOVÁ Martina
activities/1/committees/0/shadows/3
group
Verts/ALE
name
ŠOLTES Igor
activities/2/committees/0/shadows/1/group
Old
NI
New
S&D
activities/2/committees/0/shadows/1/mepref
Old
53b2d70eb819f205b0000008
New
4f1ac627b819f25efd000021
activities/2/committees/0/shadows/1/name
Old
ALIOT Louis
New
BALČYTIS Zigmantas
activities/2/committees/0/shadows/2
group
ALDE
name
DLABAJOVÁ Martina
activities/2/committees/0/shadows/3
group
Verts/ALE
name
ŠOLTES Igor
committees/0/shadows/1/group
Old
NI
New
S&D
committees/0/shadows/1/mepref
Old
53b2d70eb819f205b0000008
New
4f1ac627b819f25efd000021
committees/0/shadows/1/name
Old
ALIOT Louis
New
BALČYTIS Zigmantas
committees/0/shadows/2
group
ALDE
name
DLABAJOVÁ Martina
committees/0/shadows/3
group
Verts/ALE
name
ŠOLTES Igor
activities/3/docs/0/text
  • The Committee on Budgetary Control adopted the report by Ryszard CZARNECKI (ECR, PL) on discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines (IMI) for the financial year 2013.

    It called on the European Parliament to postpone its decision on granting the Executive Director of IMI 2 discharge in respect of the implementation of the budget of the Joint Undertaking for the implementation of the IMI for the financial year 2013.

    Members postponed the closure of the accounts of the Joint Undertaking for the financial year 2013. At the same time, they made a number of recommendations that needed to be taken into account when the discharge is granted, in addition to the general recommendations that appear in the draft resolution on performance, financial management and control of EU agencies.

    • Budgetary and financial management: Members noted that the error rate resulting from audits was at 5.82%, which meant that a qualified opinion was issued on the legality and the regularity of the transactions underlying the accounts of the Joint Undertaking, in view of the fact that the rate was above the materiality threshold of 2%.  Whilst acknowledging that follow-up actions related to audited beneficiaries with detected errors were launched, Members asked for an action plan with clear objectives aimed at fixing the deficiencies and errors identified by the Court to be submitted to the discharge authority in a timely manner. Members also asked IMI 2 to provide the discharge authority with detailed information on the in-kind contributions of EFPIA companies especially on the type of the in-kind contributions and their respective value. They also called on the Joint Undertaking to submit a report to the discharge authority concerning the contributions of all members other than the Commission including the application of the methodology for evaluating in-kind contributions, together with an assessment by the Commission.
    • Internal control: the committee observed that the Commission's Internal Audit Service (IAS) performed an assurance engagement of project management and reporting on operational performance, and included recommendations regarding improvements particularly regarding risk assessment of the Joint Undertaking's specific IT systems as well as the common infrastructure it shares with the FCH, Clean Sky, ENIAC and ARTEMIS Joint Undertakings.

    Members went on to make a series of observation on conflicts of interests at the Joint Undertaking as well as on the management of calls for proposals and the legal framework of IMI 2.

    Other observations: lastly, the committee called on IMI 2 to submit a report to the discharge authority on the social-economic benefits of the already completed projects and for that report to be submitted to the discharge authority together with an assessment by the Commission. It recalled that the discharge authority had previously requested the Court to draw up a special report on the capacity of the joint undertakings, together with their private partners, to ensure added value and efficient execution of Union research, technological development and demonstration programmes.

activities/5
date
2015-04-29T00:00:00
body
EP
type
Vote in plenary scheduled
activities/4/type
Old
Indicative plenary sitting date, 1st reading/single reading
New
Debate in plenary scheduled
activities/3/docs
  • url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2015-0106&language=EN type: Committee report tabled for plenary, single reading title: A8-0106/2015
activities/3
date
2015-03-31T00:00:00
body
EP
type
Committee report tabled for plenary, single reading
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament 1st reading / single reading / budget 1st stage
activities/2
date
2015-03-23T00:00:00
body
EP
type
Vote in committee, 1st reading/single reading
committees
activities/2
date
2015-03-23T00:00:00
body
EP
type
Vote scheduled in committee, 1st reading/single reading
activities/2/date
Old
2015-03-24T00:00:00
New
2015-03-23T00:00:00
activities/0/commission/0
DG
Commissioner
GEORGIEVA Kristalina
other/0
body
EC
dg
commissioner
GEORGIEVA Kristalina
activities/0/docs/0/text
  • PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2013, as part of the 2013 discharge procedure.

    Analysis of the accounts of the Joint Technology Initiative on Innovative Medicines (IMI).

    CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2013 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the IMI Joint Undertaking.

    The document contains the figures on which the discharge procedure is based.

    Discharge procedure of the EU Joint Undertakings: the EU Budget finances a wide range of policies and programmes throughout the EU. In accordance with the priorities set by the European Parliament and the Council in the multi-annual financial framework (MFF), the European Commission carries out specific programmes, activities and projects in the field with the technical support of some specialised agencies.

    The consolidated annual accounts of the EU provide information on the activities of the institutions, agencies and other bodies of the EU from a budgetary and accrual accounting perspective.

    The consolidated reports on the implementation of the general budget of the EU include the budget implementation of all Institutions. Agencies and Joint Undertakings (JUs) do not have a separate budget inside the EU budget; and they are partially financed by a Commission budget subsidy.

    Each JU is subject to its own discharge procedure.

    IMI: in 2013, the tasks and budget of the Joint Undertaking were as follows:

    • description of the tasks of the Joint Undertaking: the IMI Joint undertaking, which is located in Brussels, was set up in 2007 by Council Regulation (EC) No 73/2008 for a period of 10 years. The IMI Joint Undertaking supports pre-competitive pharmaceutical research and development in the Member States and associated countries, aiming at increasing the research investment in the biopharmaceutical sector and promotes the involvement of small and medium-sized enterprises (SME) in its activities;
    • accounts of the JU: the maximum indicative contribution of the Commission to cover running costs and research activities is EUR 1 billion up to 31.12.2017. The cumulative unrecognised share of losses is EUR 16 million.

    Please also consult the final accounts of IMI Joint Undertaking.

activities/1/committees/0/shadows/1
group
EFD
name
VALLI Marco
committees/0/shadows/1
group
EFD
name
VALLI Marco
activities
  • date: 2014-07-30T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2014/0510/COM_COM(2014)0510_FR.pdf celexid: CELEX:52014DC0510:EN type: Non-legislative basic document published title: COM(2014)0510 body: EC type: Non-legislative basic document published commission:
  • date: 2014-10-20T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP shadows: group: EPP name: MARINESCU Marian-Jean group: NI name: ALIOT Louis responsible: True committee: CONT date: 2014-09-26T00:00:00 committee_full: Budgetary Control rapporteur: group: ECR name: CZARNECKI Ryszard body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
  • date: 2015-03-24T00:00:00 body: EP type: Vote scheduled in committee, 1st reading/single reading
  • date: 2015-04-28T00:00:00 body: EP type: Indicative plenary sitting date, 1st reading/single reading
committees
  • body: EP shadows: group: EPP name: MARINESCU Marian-Jean group: NI name: ALIOT Louis responsible: True committee: CONT date: 2014-09-26T00:00:00 committee_full: Budgetary Control rapporteur: group: ECR name: CZARNECKI Ryszard
  • body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI
  • body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
links
other
    procedure
    dossier_of_the_committee
    CONT/8/01601
    reference
    2014/2133(DEC)
    title
    2013 discharge: IMI Joint Undertaking for the implementation of the Joint Technology Initiative on Innovative Medicines
    stage_reached
    Awaiting committee decision
    type
    DEC - Discharge procedure
    subject
    8.70.03.03 2013 discharge